Melanoma drug combo gets a smarter schedule
NCT ID NCT03543969
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 29 times
Summary
This early-phase study tested a new way of giving three drugs (encorafenib, binimetinib, and nivolumab) to people with advanced BRAF-mutant melanoma. Instead of taking the drugs every day, participants followed an on/off schedule to see if it could control the cancer while reducing side effects. The study enrolled 14 adults with stage IIIC to IV melanoma that could not be removed by surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SKIN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.